A new study called SKINDLE will test an experimental skin ointment for active skin lesions caused by Discoid or Systemic Lupus Erythematosus. The drug, called R333, is a potent, topical JAK and SYK inhibitor with the potential to prevent or diminish both acute and chronic phases of this disorder. DLE is a chronic skin condition of sores with inflammation and scarring favoring the face, ears, and scalp and at times on other body areas. To view Rigel's animation on R333 in DLE, go to www.rigel.com/rigel/discoid_lupus.
Dr. Daniel Wallace, founder of Lupus LA and member of the S.L.E. Lupus Foundation's Board of Directors, is conducting the study at the Wallace Rheumatic Study Center in Los Angeles. He can be contacted at 310-360-9197. Other clinics around the country where the study is being conducted can be found at:http://www.centerwatch.com/clinical-trials/listings/external-studydetails.aspx?StudyID=NCT01597050.
Visit the Number 1 site for information on lupus trials, LupusTrials.org to learn more about this trial and others that might be right for you.